GET THE APP

Extracellular matrix-assisted cell viability | 27139
Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

+44 1300 500008

Extracellular matrix-assisted cell viability


5th World Congress on Cell & Stem Cell Research

March 23-25, 2015 DoubleTree by Hilton Chicago - North Shore, USA

Christopher A Bradley

Scientific Tracks Abstracts: J Cell Sci Ther

Abstract :

Decellularized tissue matrices derived from cadaveric sources provide allografts used in surgical applications such as spinal fusion, tendon replacement, breast reconstruction, and dermal wound healing. The emergent technology of adult stem cells promises to augment these traditional surgical materials to create medical treatments that are truly regenerative. The next generation of allografts that will be self-healing and superior to previous implementations will require the application of stem cells and stem cell-derived technologies. In the case of bone tissue, osteoinductive properties of demineralized bone matrix are retained and can direct differentiation of recruited stem cells to promote healing. However, cell homing, retention, and vascularization at the lesion site could be greatly improved. Research to define the niche specified by stem cell-secreted extracellular matrix (ECM) has allowed for customization of the ideal healing microenvironment. Allografts infused with stem-cell derived ECM can potentially provide all the necessary signals that would improve engraftment and viability of recruited stem cells. Additionally, manipulation of the growth conditions under which stem cells produce their ECM could revive quiescent cells and enhance vascularization. Lattice Biologics seeks to develop the next generation of allografts. We envision using fluorescent chimeric RNA aptamers to measure important metabolite ratios in living cells and select for conditions ideal for autologous stem cell transplantation. Similarly, optimization of conditions used to grow stem cells in vitro could influence the output of soluble and insoluble signals present in secreted ECM which would then be used to instruct a patient?s own circulating stem cells.

Biography :

Christopher A Bradley (PhD), began his scientific research career in the field of Translational Control of Gene Expression at Louisiana State University Health Sciences Center in Shreveport, Louisiana. He has held several Postdoctoral research positions within the University of California Davis Health System performing research in the fields of proteomics, head-and-neck cancer and osteoarthritis. His academic experience in Arizona involving virology and nucleocytoplasmic trafficking prepared him for industry positions in nutraceuticals and regenerative medicine. He currently serves in stem cell product development as Project Manager for Lattice Biologics, a certified tissue bank and manufacturer of surgical allografts.

Top